Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors

被引：0
|
作者：
Tonini, Matthew R.
Mignault, Andre A.
Whittington, Douglas A.
Lombardo, Steven A.
Shen, Binzhang
Stowe, Hannah
Yoda, Satoshi
Liu, Shangtao
Zhang, Minjie
Cottrell, Kevin M.
Meier, Samuel R.
Rego, Heidi
Morawiak, Jennifer
Hooper, Ellen
Yu, Yi
DiBenedetto, Heather
Crystal, Adam S.
Teng
Briggs, Kimberly
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4631
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor
    Liang, Jianglin Colin
    Li, Hongming
    Cottrell, Kevin M.
    Liu, Yong
    Maxwell, John P.
    Xin, Zhengyang
    Anzalone, Luigi
    Ronn, Magnus
    Palmieri Jr, Michael A.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2025, 29 (03) : 946 - 952
  • [42] From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
    Sarvary, Ian
    Vestergaard, Mikkel
    Moretti, Loris
    Andersson, Jan
    Cadahia, Jorge Peiro
    Cowland, Sanne
    Flagstad, Thomas
    Franch, Thomas
    Gouliaev, Alex
    Husemoen, Gitte
    Jacso, Tomas
    Kronborg, Titi
    Kuropatnicka, Aleksandra
    Nadali, Anna
    Madsen, Mads
    Nielsen, Soren
    Pii, David
    Ryborg, Soren
    Soede, Camillia
    Allen, Jennifer R.
    Bourbeau, Matthew
    Li, Kexue
    Liu, Qingyian
    Lo, Mei-Chu
    Madoux, Franck
    Mardirossian, Narbe
    Moriguchi, Jodi
    Ngo, Rachel
    Peng, Chi-Chi
    Pettus, Liping
    Tamayo, Nuria
    Wang, Paul
    Kapoor, Rajiv
    Belmontes, Brian
    Caenepeel, Sean
    Hughes, Paul
    Liu, Siyuan
    Slemmons, Katherine K.
    Yang, Yajing
    Xie, Fang
    Ghimire-Rijal, Sudipa
    Mukund, Susmith
    Glad, Sanne
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (06) : 6534 - 6557
  • [43] Discovery of a highly MTA-synergistic series of PRMT5 inhibitors for the treatment of MTAP-deficient tumors by virtual screening technology
    Parr, B.
    DeMarco, K.
    Dhanave, A.
    Evangelista, E.
    Frye, L.
    Gerken, P.
    Johnson, Z.
    Kapilashrami, K.
    Lakshminarasimhan, D.
    Lawrenz, M.
    Leffler, A.
    Maw, J.
    Samkutty, A.
    Silvergleid, S.
    So, S. S.
    Svensson, M.
    Thigale, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S140 - S141
  • [44] MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Induces Cell Cycle Arrest and Synergizes With Oxaliplatin and Gemcitabine for Enhanced Anticancer Effects
    Soeta, Toshihiro
    Sugisawa, Norihiko
    Yamamura, Akihiro
    Tanaka, Naoki
    Imoto, Hirofumi
    Tsuchiya, Takahiro
    Aizawa, Takashi
    Okamoto, Koji
    Kawamura, Mari
    Saijo, Fumito
    Mizuma, Masamichi
    Ohnuma, Shinobu
    Kamei, Takashi
    Unno, Michiaki
    ANTICANCER RESEARCH, 2024, 44 (12) : 5231 - 5240
  • [45] The discovery and preclinical characterization of the MTA cooperative PRMT5 inhibitor AM-9747
    Belmontes, Brian
    Policheni, Antonia
    Liu, Siyuan
    Slemmons, Katherine
    Moriguchi, Jodi
    Ma, Hayley
    Aiello, Daniel
    Yang, Yajing
    Vestergaard, Mikkel
    Cowland, Sanne
    Anderson, Jan
    Sarvary, Ian
    Tamayo, Nuria
    Pettus, Liping
    Mukund, Susmith
    Pope, Leszek
    Allen, Jennifer R.
    Glad, Sanne
    Bourbeau, Matthew
    Hughes, Paul E.
    CANCER RESEARCH, 2022, 82 (12)
  • [46] Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors
    Rodon, Jordi
    Yamamoto, Noboru
    Doi, Toshihiko
    Ghiringhelli, Francois
    Goebeler, Maria-Elisabeth
    Fujuwara, Yutaka
    Villalona-Calero, Miguel
    Penel, Nicolas
    Patnaik, Amita
    Machiels, Jean-Pascal
    Addeo, Alfredo
    Abbruzzese, James
    Postel-Vinay, Sophie
    Rottey, Sylvie
    Liu, Chunxu
    Chuang, Chen-Hua
    Kormany, William
    Hughes, Paul
    Keyvanjah, Kiana
    O'Neil, Bert
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [47] Phase 1b Study of AMG 193, An MTA-Cooperative PRMT5i, Alone and in Combination with Other Therapies in MTAP-deleted NSCLC
    Spira, A.
    Sacher, A.
    Paz-Ares Rodriguez, L.
    Felip, E.
    Reguart, N.
    Desar, I.
    Punekar, S.
    Dy, G.
    Fontana, E.
    Udagawa, H.
    El Helali, A.
    Menis, J.
    Hummel, H. -D.
    Itsara, A.
    Eggert, T.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S350 - S350
  • [48] Study on biological activity of various truncations of human PRMT5 in E. coli
    Sun Li-Tao
    Zhou Zhong-Wei
    Xie Xiao-Dong
    Bao Shi-Lai
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2008, 35 (07) : 801 - 806
  • [49] Identification of a novel series of MTAP-selective PRMT5 inhibitors, and first disclosure of AZ-PRMT5i-1
    Smith, James M.
    Barlaam, Bernard
    Beattie, David
    Cumming, Iain
    Robb, Graeme
    Wilson, David
    Gianni, Davide
    Srinivasan, Bharath
    Stubbs, Chris
    Debreczeni, Judit
    Vazquez-Chantada, Mercedes
    Chiarparin, Elisabetta
    Lynch, James
    Dean, Emma
    CANCER RESEARCH, 2023, 83 (07)
  • [50] A novel MTAcooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers
    Vegar, Laura
    Aranda, Ruth
    Waters, Laura
    Moya, Krystal
    Hebbert, Allan
    Smith, Christopher S.
    Hallin, Jill
    David, Briere M.
    Engstrom, Lars D.
    Vanderpool, Darin
    Marx, Matthew M.
    Christensen, James G.
    Olson, Peter A.
    CANCER RESEARCH, 2023, 83 (07)
12345